These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 36458050)
1. Update on the first-line treatment of Shih CA; Shie CB; Hsu PI Therap Adv Gastroenterol; 2022; 15():17562848221138168. PubMed ID: 36458050 [TBL] [Abstract][Full Text] [Related]
2. Update on the first-line treatment for Huang CC; Tsai KW; Tsai TJ; Hsu PI Biomark Res; 2017; 5():23. PubMed ID: 28702193 [TBL] [Abstract][Full Text] [Related]
3. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915 [TBL] [Abstract][Full Text] [Related]
4. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326 [TBL] [Abstract][Full Text] [Related]
5. Real-world practice and Expectation of Asia-Pacific physicians and patients in Helicobacter Pylori eradication (REAP-HP Survey). Chuah YY; Wu DC; Chuah SK; Yang JC; Lee TH; Yeh HZ; Chen CL; Liu YH; Hsu PI Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28244264 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection. Kim YJ; Chung WC; Kim DB Helicobacter; 2021 Jun; 26(3):e12792. PubMed ID: 33650225 [TBL] [Abstract][Full Text] [Related]
8. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366 [TBL] [Abstract][Full Text] [Related]
9. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Suzuki S; Gotoda T; Kusano C; Ikehara H; Ichijima R; Ohyauchi M; Ito H; Kawamura M; Ogata Y; Ohtaka M; Nakahara M; Kawabe K Gut; 2020 Jun; 69(6):1019-1026. PubMed ID: 31915235 [TBL] [Abstract][Full Text] [Related]
10. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163 [TBL] [Abstract][Full Text] [Related]
11. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial. Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636 [TBL] [Abstract][Full Text] [Related]
12. Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial. Zhou L; Zhang J; Song Z; He L; Li Y; Qian J; Bai P; Xue Y; Wang Y; Lin S Helicobacter; 2016 Apr; 21(2):91-9. PubMed ID: 26104022 [TBL] [Abstract][Full Text] [Related]
13. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS; Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562 [TBL] [Abstract][Full Text] [Related]
14. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Li M; Oshima T; Horikawa T; Tozawa K; Tomita T; Fukui H; Watari J; Miwa H Helicobacter; 2018 Aug; 23(4):e12495. PubMed ID: 29873436 [TBL] [Abstract][Full Text] [Related]